GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Genfit S.A.
Genfit is a French biopharmaceutical company focused on the treatment of liver diseases. The price of its ADRs on NASDAQ is highly volatile and depends on the results of clinical trials of its drugs, regulatory decisions in the US and Europe, and partnerships with major pharmaceutical companies.
Share prices of companies in the market segment - Pharma liver
Genfit S.A. is a French biopharmaceutical company developing drugs for the treatment of liver diseases and metabolic disorders. We have classified it in the Pharma: Liver category. The chart below shows investor sentiment in this promising but risky biotech segment.
Broad Market Index - GURU.Markets
Genfit is a French biopharmaceutical company developing drugs for the treatment of liver diseases and metabolic disorders. It is a component of the GURU.Markets index. The chart below shows the US market. See how this company's stock compares to the US market trend.
Change in the price of a company, segment, and market as a whole per day
GNFT - Daily change in the company's share price Genfit S.A.
The daily fluctuations of Genfit, a biopharmaceutical company, reflect the inherent volatility of the sector. Change_co measures the reaction to research data and regulatory decisions. This metric is important for analyzing risks and opportunities in biotech on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma liver
Genfit S.A. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with GNFT, which focuses on liver disease treatments, helps to assess it as a high-risk, clinically data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Genfit is a French biopharmaceutical company developing drugs for the treatment of liver diseases and fibrosis. This is a highly competitive and risky field. The chart below shows the segment's volatility, helping to assess how typical Genfit's dynamics are for this niche.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Genfit S.A.
Genfit S.A.'s year-over-year performance tells the story of its strategic pivot following the failure of its NASH drug development. Its market capitalization over the past 12 months reflects its success in developing new programs for treating rare liver diseases and its transformation into a company focused on narrower, yet more promising, niches.
Annual dynamics of market capitalization of the market segment - Pharma liver
Genfit S.A. is a late-stage French biotech company developing drugs for the treatment of liver diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this complex area of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Genfit is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its share price (ADR) reflects investor expectations for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Genfit S.A.
The market capitalization of Genfit, a biopharmaceutical company, depends on its R&D cycle. Monthly fluctuations on the chart reflect news about clinical trials of its liver disease drugs, the success of which determines its future valuation and partnerships with major pharmaceutical companies.
Monthly dynamics of market capitalization of the market segment - Pharma liver
Genfit S.A. is a biopharmaceutical company focused on liver diseases. This biotech segment is attracting significant attention due to the prevalence of diseases like NASH, but is also characterized by high risks in clinical development. The chart below shows how investor sentiment toward the entire sector has changed based on news from leading players.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Genfit is a French biopharmaceutical company specializing in liver and metabolic diseases. Its shares move in sync with news about clinical trials and decisions by European and American regulators. This is a high-risk bet on success in one of the most complex areas of medicine.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Genfit S.A.
Shares of Genfit, a French biopharmaceutical company focused on liver diseases, are extremely volatile. Weekly price movements depend entirely on the results of clinical trials of their drug candidates. The chart below illustrates how hopes and disappointments in this complex area of medicine drive sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma liver
How does Genfit's performance compare to the broader biotech sector? This chart compares the French company's weekly share price movements to the overall trend. This helps us understand whether its move, driven by news about a liver treatment, is a unique event or a reflection of overall investor sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Genfit is a French biopharmaceutical company specializing in liver diseases. This chart shows how its weekly performance is detached from the market. Its stock moves are driven by news about clinical trials and regulatory decisions, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
GNFT - Market capitalization of the company Genfit S.A.
The valuation of Genfit S.A. is a story of hope and disappointment in the search for a cure for metabolic steatohepatitis (MASH). The French biotech's market cap now depends on its ability to refocus its research on other liver diseases after the failure of its key drug.
GNFT - Share of the company's market capitalization Genfit S.A. within the market segment - Pharma liver
Genfit S.A. is a French biopharmaceutical company whose market share is based on its long-standing research in liver diseases and metabolism. Its market capitalization reflects its emerging strategy and development pipeline.
Market capitalization of the market segment - Pharma liver
Here's a chart of the total market capitalization of biotech companies focused on liver diseases. Genfit is one of the European pioneers in this field. The graph shows how the market values this complex but vast niche, where there are currently no approved drugs for NASH.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph visualizes hope for patients with liver disease. The market capitalization of Genfit S.A., a French biopharmaceutical company, reflects its scientific developments in this complex field. The line shows how European science is competing for its share of the global market for metabolic disorders.
Book value capitalization of the company, segment and market as a whole
GNFT - Book value capitalization of the company Genfit S.A.
Genfit S.A.'s book value represents its scientific capital. The chart below reflects the valuation of its pipeline of developments targeting liver diseases and metabolic disorders. The pipeline's growth reflects success in clinical trials, which are the primary tangible embodiment of this biotech company's value.
GNFT - Share of the company's book capitalization Genfit S.A. within the market segment - Pharma liver
For Genfit, a biopharmaceutical company focused on liver diseases, its tangible assets are its cutting-edge laboratories and scientific equipment. The chart shows the company's share of this highly specialized scientific infrastructure, which forms the physical basis for combating metabolic diseases.
Market segment balance sheet capitalization - Pharma liver
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Genfit, which develops drugs for liver diseases, looks "light." Its value lies in its patents and scientific data, not in large factories. Its business is science.
Book value of all companies included in the broad market index - GURU.Markets
Genfit is a French biopharmaceutical company developing treatments for liver diseases. The company's assets are not its plants, but rather its intellectual property and clinical trial data. The company's balance sheet is the value of its scientific research into a solution to one of the most common and real health problems.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Genfit S.A.
Genfit's balance sheet consists of its cash and R&D. A market capitalization close to its cash value suggests that investors have written off its previous failures and don't see much value in its future projects. A graph showing MvsBCap_Co ≈ 1 indicates the company's value as a "piggy bank."
Market to book capitalization ratio in a market segment - Pharma liver
Genfit is a French biopharmaceutical company. The chart shows the speculative valuation of its research and development in the field of liver diseases and metabolism. The valuation is highly dependent on clinical trial results and regulatory decisions.
Market to book capitalization ratio for the market as a whole
Genfit is a biopharmaceutical company specializing in developing treatments for liver and metabolic disorders. Its value is determined by the success of its clinical programs. This chart shows how the market values biotech companies working to address common chronic diseases.
Debts of the company, segment and market as a whole
GNFT - Company debts Genfit S.A.
Genfit, a biopharmaceutical company focused on liver diseases, uses debt to finance its clinical programs. This chart shows how the company raises capital to support expensive research and development of new treatments. In the biotech world, debt is a vital resource on the long road to commercialization.
Market segment debts - Pharma liver
Genfit is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. Drug development in this field is a long and risky process. This chart shows how the company funds its expensive research and development at the clinical stage.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Genfit S.A.
Genfit is a French biopharmaceutical company specializing in liver diseases. This chart shows its reliance on debt to finance lengthy and expensive clinical trials. For a company operating in a complex medical field, high debt poses a significant risk, as the success of its research depends on it.
Market segment debt to market segment book capitalization - Pharma liver
Genfit is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. Drug development in this field is a long and expensive process. The chart shows how the company's debt load relates to the market capitalization and risks of the overall biotech sector.
Debt to book value of all companies in the market
Genfit (GNFT) is a French late-stage biopharmaceutical company specializing in liver diseases. This chart shows the overall debt burden of the economy. It serves as a contrast to Genfit's financial model, which will likely rely on equity rather than debt until the commercialization of its lead drug.
P/E of the company, segment and market as a whole
P/E - Genfit S.A.
This metric for the French biopharmaceutical company Genfit reflects its long and complex history in developing drugs for liver diseases. There is no P/E. The company's valuation, after past setbacks, now depends on the success of its new programs and its ability to restore investor confidence in its scientific platform.
P/E of the market segment - Pharma liver
This industry metric represents the average P/E for biotech companies. For Genfit, after its past failures, it's a stark benchmark. It reflects how more successful companies are valued and helps understand the discount investors are pricing in for the risks associated with its ability to restore confidence and bring new drugs to market.
P/E of the market as a whole
Genfit is a late-stage French biopharmaceutical company focused on liver diseases and metabolic disorders. The company develops treatments for rare but serious diseases. This risk appetite chart helps understand how investors value European biotech companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Genfit S.A.
Genfit is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. This graph reflects the company's research and development expectations. This assessment depends on the results of clinical trials and the company's ability to bring new treatments to market for common conditions such as nonalcoholic steatohepatitis (NASH).
%20P%2FE%20Genfit%20S.A.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Genfit-S.A.&v=1772679292908 "Chart of the company's future (projected) P/E Genfit S.A.")
Future (projected) P/E of the market segment - Pharma liver
Genfit is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. This chart reflects the company's long-term profitability expectations. It shows how the market views their scientific developments and their ability to develop a marketable drug in this complex therapeutic area.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-liver&v=1772679292973 "Future (projected) P/E graph of the market segment - Pharma liver")
Future (projected) P/E of the market as a whole
Genfit is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. Its future depends on the success of its clinical developments. This market expectations chart reflects investor willingness to finance risky biotech projects. Market optimism facilitates Genfit's capital raising.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772679293032 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Genfit S.A.
Genfit is a French biopharmaceutical company specializing in the development of drugs for the treatment of liver diseases and metabolic disorders. Its financial results reflect the costs of conducting clinical trials in these complex and widespread areas of medicine.
Profit of companies in the market segment - Pharma liver
Genfit is a French biotech company specializing in liver diseases and metabolic disorders. Its financial performance reflects its high clinical research expenditures. This biotech chart shows how European companies contribute to the global drug discovery effort, shaping the overall picture.
Overall market profit
Genfit is a French biopharmaceutical company specializing in liver diseases. Its future depends on the results of clinical trials and the approval of its drugs. This is a high-risk venture, the value of which is determined by scientific data, not by the macroeconomic indicators that shape the overall picture in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Genfit S.A.
Genfit is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. This schedule reflects expectations, which depend on the success of its clinical programs. Partnerships and progress in developing drugs for rare liver diseases are key factors in the outlook.
%20profit%20of%20the%20company%20Genfit%20S.A.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Genfit-S.A.&v=1772679293216 "Graph of future (projected) profit of the company Genfit S.A.")
Future (predicted) profit of companies in the market segment - Pharma liver
Genfit is a French biopharmaceutical company focused on developing treatments for liver diseases and metabolic disorders. This chart shows the revenue forecast for the entire pharmaceutical sector. It reflects expectations for breakthroughs in the treatment of nonalcoholic steatohepatitis (NASH), which is key to assessing the potential of Genfit's developments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-liver&v=1772679293313 "Graph of future (predicted) profits of companies in a market segment - Pharma liver")
Future (predicted) profit of the market as a whole
Genfit is a French biopharmaceutical company focused on liver diseases. Its future depends on the results of clinical trials and partnerships. The overall investment climate, which can be assessed from this chart, determines the availability of funding for the biotech sector and the willingness of large companies to acquire promising developments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772679293350 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Genfit S.A.
Genfit is a French biopharmaceutical company specializing in the development of drugs for the treatment of liver diseases and metabolic disorders. This chart shows how investors view its scientific developments after shifting its strategy and focusing on new, more promising programs following past setbacks.
P/S market segment - Pharma liver
Genfit is a late-stage French biopharmaceutical company focused on developing treatments for metabolic and liver diseases, particularly primary biliary cholangitis (PBC). This chart shows the average valuation in the sector, providing insight into how the market views Genfit's clinical pipeline and product candidates.
P/S of the market as a whole
Genfit is a French biopharmaceutical company specializing in developing treatments for liver and metabolic disorders. This is an area with a significant unmet need. This market valuation chart helps understand the premium investors are paying for this potentially disruptive, yet risky, biotech revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Genfit S.A.
Genfit is a biopharmaceutical company specializing in liver diseases. Being in the clinical stage, it is evaluated based on its future potential. This chart reflects investor expectations for the success of its clinical programs and the commercialization of future drugs.
%20P%2FS%20Genfit%20S.A.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Genfit-S.A.&v=1772679293444 "The graph of the company's future (projected) P/S Genfit S.A.")
Future (projected) P/S of the market segment - Pharma liver
Genfit is a French biopharmaceutical company specializing in liver and metabolic diseases. This chart compares market expectations for its future revenue with those of other companies working in the liver treatment field. The valuation reflects investor opinions on its clinical pipeline and diagnostic technologies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20liver&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-liver&v=1772679293493 "Future (projected) P/S market segment graph - Pharma liver")
Future (projected) P/S of the market as a whole
Genfit is a French biotech company specializing in liver diseases. Its success depends on the results of clinical trials. The overall market optimism, reflected in this chart, creates a favorable environment for raising the capital needed to advance innovative drugs through the long and costly development process.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772679293528 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Genfit S.A.
Genfit is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. Currently in the clinical stage, its revenue comes from partnerships with major pharmaceutical companies. The chart shows the financial flows that enable the company to conduct research in these complex areas of medicine.
Sales of companies in the market segment - Pharma liver
Genfit is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. After the failure of its NASH drug, the company shifted its focus to rare liver diseases. Revenue comes from partnerships. This chart illustrates the complex and risky path of drug development, where the company must adapt its strategy based on clinical results.
Overall market sales
Genfit is a French biopharmaceutical company focused on liver diseases. Its future depends on the success of its clinical trials. The connection to economic cycles reflected in this chart is indirect—through its impact on the overall investment attractiveness of the biotech sector and the availability of financing.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Genfit S.A.
Genfit is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. Following the failure of its NASH drug development, the company shifted its focus to other rare liver diseases. This graph reflects analyst expectations for the success of its new clinical programs.
%20sales%20of%20the%20company%20Genfit%20S.A.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Genfit-S.A.&v=1772679293878 "Schedule of future (projected) sales of the company Genfit S.A.")
Future (projected) sales of companies in the market segment - Pharma liver
Genfit is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. This chart shows the overall outlook for the pharmaceutical industry. It helps analyze how the company is refocusing its research after failures in one area and the prospects for its new developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-liver&v=1772679293945 "Schedule of future (projected) sales of companies in the market segment - Pharma liver")
Future (projected) sales of the market as a whole
Genfit S.A. is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. This chart, reflecting the biotech investment climate, is important for the company. Drug development in these complex areas requires significant capital, and the availability of funding is directly dependent on overall economic sentiment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772679294025 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Genfit S.A.
Genfit S.A. is a late-stage biopharmaceutical company specializing in metabolic and liver diseases. Its business involves years of scientific research and costly clinical trials. This chart reflects the company's financial trajectory as it strives to bring new treatments for complex chronic diseases to market.
Market segment marginality - Pharma liver
Genfit S.A. is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. Being in clinical trials, the company incurs significant R&D expenditures. This chart reflects the level of investment in their scientific platform, which, if successful, could yield very high returns.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Genfit S.A.
Genfit is a French biotech company specializing in liver diseases and metabolic disorders. This graph shows the team of scientists and clinicians. The headcount dynamics reflect the ups and downs associated with clinical trial results, which is typical for this sector.
Share of the company's employees Genfit S.A. within the market segment - Pharma liver
Genfit is a biopharmaceutical company specializing in liver diseases and metabolic disorders. This chart shows its market share in the pharmaceutical sector. It reflects the team of scientists and clinicians working to develop new diagnostic tools and treatments aimed at solving complex liver health problems.
Number of employees in the market segment - Pharma liver
Genfit S.A. is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. This chart illustrates employment in the pharmaceutical sector. The dynamics of personnel, particularly research staff, reflect the successes and failures of the lengthy and expensive clinical trials typical of this field.
Number of employees in the market as a whole
Genfit S.A. is a French biopharmaceutical company specializing in the development of treatments for liver diseases such as non-alcoholic steatohepatitis (NASH). This chart shows the overall labor market, and research-intensive companies like Genfit are an important part of the global healthcare ecosystem, creating jobs for world-class scientists and researchers.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Genfit S.A. (GNFT)
Genfit S.A. is a French biopharmaceutical company specializing in liver diseases. During the development stage, its value is determined by its pipeline of potential drugs. This chart shows a high but volatile market capitalization per employee, as the market evaluates the likelihood of clinical trial success. It is a classic example of an R&D-driven biotech business.
%20of%20the%20company%20Genfit%20S.A.%20(GNFT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Genfit-S.A.-GNFT&v=1772679294320 "Chart of market capitalization per employee (in thousands of dollars) of the company Genfit S.A. (GNFT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma liver
Genfit is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. This indicator reflects investor expectations for its clinical developments. The chart shows the future value the market attributes to each of the company's scientists and how this compares to the biotech industry average.
%20by%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-liver&v=1772679294400 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma liver")
Market capitalization per employee (in thousands of dollars) for the overall market
Genfit is a French biopharmaceutical company specializing in liver diseases and metabolic disorders. Its value depends on the success of its clinical developments. This chart will reflect the market's assessment of its scientific potential, with the per-employee value reflecting investors' faith in the development of a new drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772679294460 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Genfit S.A. (GNFT)
Genfit (GNFT) is a French biopharmaceutical company focused on developing drugs for liver diseases (such as PBC). This is R&D. This chart shows the "cost of science"—the negative profit (expenses) per scientist working on their clinical programs.
%20Chart%20Genfit%20S.A.%20(GNFT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Genfit-S.A.-GNFT&v=1772679294467 "Company Profit Per Employee (in thousands of dollars) Chart Genfit S.A. (GNFT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma liver
Genfit S.A. is a French biopharmaceutical company specializing in the development of drugs for the treatment of liver diseases, particularly primary biliary cholangitis (PBC). Their core business is R&D. This chart shows the benchmark for personnel efficiency in biotech. It is important for assessing how effectively Genfit's scientific team utilizes its capital.
%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-liver&v=1772679294522 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma liver")
Profit per employee (in thousands of dollars) for the market as a whole
Genfit S.A. (GNFT) is a French biotech company historically focused on developing drugs for liver diseases (e.g., NAFLD/NASH). This is a complex area of R&D with numerous failures. The chart shows the R&D investment (negative return) per scientist in the effort to find effective treatments for these complex diseases.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772679294564 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Genfit S.A. (GNFT)
Genfit is a French biopharmaceutical company specializing in liver diseases. This chart reflects its status as an R&D company. Revenue per employee, if any, likely comes from partnerships with major pharmaceutical companies, as the team's primary focus is on clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Genfit-S.A.-GNFT&v=1772679294618 "Sales chart per company employee Genfit S.A. (GNFT)")
Sales per employee in the market segment - Pharma liver
Genfit (GNFT) is a late-stage French biotech focused on treating metabolic and liver diseases, particularly primary biliary cholangitis (PBC). This chart shows how much revenue (from partnerships) each employee (scientist) generates. This is an indicator of the productivity of their R&D platform.
Sales per employee for the market as a whole
Genfit S.A. (GNFT) is a French biotechnology company focused on developing drugs for the treatment of liver diseases. It is a clinical-stage R&D company. This chart reflects their model: the company generates some revenue from partnerships (upfront fees), but primarily invests in its own scientific staff to conduct clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Genfit S.A. (GNFT)
Genfit S.A. is a French biotech that failed to develop a treatment for NASH (fatty liver disease). The company is now focusing on other rare diseases. This chart shows bearish bets. The shorts are driven by the previous failure and doubts about the company's ability to succeed with its new, highly niche developments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Genfit-S.A.-GNFT&v=1772679294745 "Short Shares Chart for the Company Genfit S.A. (GNFT)")
Shares shorted by market segment - Pharma liver
Genfit (GNFT) is a French biotech company focused on treating rare liver diseases (such as PBC). This chart is a barometer of sentiment across the biotech industry. Investors shorting the sector indicate they are unsure of the success of risky R&D, especially after Genfit's previous failure to treat NASH (fatty liver disease).
Shares shorted by the overall market
Genfit is a late-stage biopharmaceutical company focused on liver diseases. Its valuation is tied to clinical trial results. While this is independent of the economy, high market fears (as shown in this chart) make it difficult for biotechs to raise the capital needed to commercialize their drugs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Genfit S.A. (GNFT)
Genfit (GNFT) is a French biotech company whose fortunes are closely tied to the development of drugs for NASH (non-alcoholic steatohepatitis, or "fatty liver disease"). It's a huge market, but with high R&D risks. This chart measures hype. It shows when the stock is "overheated" (above 70) due to positive trial data or "oversold" (below 30) due to competitors' failures or successes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Genfit-S.A.-GNFT&v=1772679294930 "RSI 14 indicator chart for the company's stock Genfit S.A. (GNFT)")
RSI 14 Market Segment - Pharma liver
Genfit (GNFT) is a biotech company focused on one of the most challenging areas in medicine: treating liver disease. This chart tracks the overall sentiment in the Pharma/Liver Disease sector. It helps investors understand whether GNFT's move is a reaction to its clinical data, or whether the entire industry is overheated by the hype surrounding the NASH breakthrough, or oversold amid repeated setbacks.
RSI 14 for the overall market
For Genfit, a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects (like liver disease). During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GNFT (Genfit S.A.)
Genfit S.A. is a French biopharmaceutical company that, following the failure of its NASH drug, has refocused on rare liver diseases such as primary biliary cholangitis (PBC). This chart shows the average price target from analysts based on their confidence in the new R&D pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GNFT-Genfit-S.A.&v=1772679295000 "A chart showing analyst consensus forecasts for the expected stock price. GNFT (Genfit S.A.)")
The difference between the consensus estimate and the actual stock price GNFT (Genfit S.A.)
Genfit (GNFT) is a French biotech focused on metabolic and liver diseases, including the infamous NASH (fatty liver disease). It's a high-risk R&D bet. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the company's R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GNFT-Genfit-S.A.&v=1772679295108 "A chart showing the difference between the consensus forecast and the actual stock price. GNFT (Genfit S.A.)")
Analyst consensus forecast for stock prices by market segment - Pharma liver
Genfit (GNFT) is a French biotech company. After failing to develop a drug for fatty liver (NASH), the company focused on rare liver diseases. This chart shows analysts' overall expectations for the liver pharma sector. It reflects whether experts believe R&D success in this complex and risky sector.
Analysts' consensus forecast for the overall market share price
Genfit is a "biotech" company (formerly "NASH," now "rare" "diseases"). It's a "risky" R&D story. This chart of overall market sentiment is important. "Optimism" = the market is "willing" to "burn" money "funding" unprofitable "biotechs." "Pessimism" = "risk aversion," and "capital" "for" R&D (like GNFT's) is "drying up."
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Genfit S.A.
Genfit (GNFT) is a French biotech that has re-energized itself after its NASH failure. Their focus now is on rare liver diseases, particularly primary biliary cholangitis (PBC). This chart represents their R&D bet. Its valuation reflects the market's faith in their second chance and the success of their new drug (Elafibranor) in this new, niche area.
AKIMA Market Segment Index - Pharma liver
Genfit S.A. is a French biotechnology company specializing in the development of drugs for the treatment of liver diseases, specifically non-alcoholic steatohepatitis (NASH). This chart shows the average index for the pharmaceutical sector. It provides investors with a benchmark for how Genfit's performance compares to the sector average for companies working on this problem.
The AKIM Index for the overall market
Genfit is a biopharmaceutical company focused on liver diseases (ACLF, cholangitis). It has a partnership with Ipsen. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this European scientific success story with commercial potential compares to overall economic trends in healthcare.
